Sanofi Diabetes
One card. Up to 12 LANTUS® SoloSTAR® pen prescriptions. Pay No More Than $25. Certain restrictions apply. Start saving & enroll now >>
For U.S. Healthcare Professionals Only
A A A

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications: Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Click here for additional Important Safety Information.

Lantus® (insulin glargine [rDNA origin] injection) Injection Instructions Video

Always check the label on your vial to be sure you have the proper insulin. Do not use a vial if it is past its expiration date. Make sure the liquid in the Lantus® vial is clear and colorless. If not, throw it away. Do not mix Lantus® with any other insulin. Always use a new needle and syringe.

First get a new vial of Lantus®. Take off the cap and leave the stopper in place. Wipe off the top of the vial with a clean swab dipped in rubbing alcohol. Now take the syringe and draw air into it equal to the dose of Lantus® you will be giving yourself.

Then push the syringe through the stopper and inject the air into the vial. That makes it easier to pull out the full amount of Lantus®. Keep the syringe in the vial and turn both upside down, making sure the tip of the needle is well within the Lantus®.

Then pull the plunger until you have the right dose. Take a look inside the syringe, if you see any air bubbles, pull the syringe straight up and tap it gently until they rise to the top. Then gently push the air bubbles and insulin all the way out with the plunger, then draw the correct dose back into the syringe.

Then pull the needle out of the vial and don't let it touch anything. Pick an area of your skin to be injected, like your upper arm, thigh, or stomach area. Clean the area with rubbing alcohol. Alcohol can sometimes sting if it is not completely dry when you inject, so wait a few seconds for it to evaporate, or pat the area dry with a sterile cotton ball.

Then lightly pinch a fold of skin, and insert the needle straight into the pinched skin the way your healthcare provider, nurse, or diabetes educator showed you.

Push the plunger slowly to inject the full dose of Lantus® , then wait ten seconds before pulling the needle straight out. Press down lightly on the area with a cotton ball or gauze, don't rub it, and that's it!

Then follow your healthcare team's instructions for throwing away the needle.

Please see the Full Prescribing Information for Lantus® (insulin glargine [rDNA origin] injection) by clicking the link below. Talk to your healthcare professional about any questions regarding administering Lantus®.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

††Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen: otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Full Prescribing Information for Lantus®
Sanofi's Commitment to Fighting Counterfeit Drugs

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Full Prescribing Information for Lantus®
Sanofi's Commitment to Fighting Counterfeit Drugs

Bookmark this page
or add it to your home screen
for quick access